{"id":360258,"date":"2025-11-06T17:26:13","date_gmt":"2025-11-06T17:26:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/360258\/"},"modified":"2025-11-06T17:26:13","modified_gmt":"2025-11-06T17:26:13","slug":"trumprx-to-offer-discount-weight-loss-drugs-after-lilly-novo-deals","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/360258\/","title":{"rendered":"TrumpRx to offer discount weight loss drugs after Lilly, Novo deals"},"content":{"rendered":"<p>WASHINGTON \u2014 The Trump administration announced a deal Thursday to expand access to <a href=\"https:\/\/www.statnews.com\/2023\/09\/12\/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly\/\" rel=\"nofollow noopener\" target=\"_blank\">popular obesity drugs<\/a> made by Novo Nordisk and Eli Lilly \u2014 offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board.<\/p>\n<p>The administration argued that giving millions more people access to these drugs represents a major victory in the fight against chronic disease.\u00a0The precise timeline for the coverage expansion and the extent of who will gain access remain unclear.<\/p>\n<p>Medicare and Medicaid will receive substantial discounts on the drugs, and will cover them to help some overweight and obese individuals lose weight. The companies have agreed to sell the treatments for $245 a month across both programs for weight loss and to help treat diabetes, senior administration officials familiar with the deal told reporters. Medicare beneficiaries will have a $50 copay.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON \u2014 The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by&hellip;\n","protected":false},"author":3,"featured_media":360259,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[150,11399,47230,25996,210,1141,1142,3170,3235,9412,10943,152,153,154,67,132,68],"class_list":{"0":"post-360258","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-biotechnology","9":"tag-chronic-disease","10":"tag-drug-prices","11":"tag-eli-lilly","12":"tag-health","13":"tag-health-care","14":"tag-healthcare","15":"tag-medicaid","16":"tag-medicare","17":"tag-novo-nordisk","18":"tag-obesity","19":"tag-pharmaceuticals","20":"tag-policy","21":"tag-stat","22":"tag-united-states","23":"tag-unitedstates","24":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115503929392417964","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/360258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=360258"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/360258\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/360259"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=360258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=360258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=360258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}